CMBC International: Hung Teng Precision (06088) has strong business prospects, target price raised to 7.33 Hong Kong dollars.
Due to the improved income structure of AI, the company expects that Hongteng Precision's gross profit margin and net profit margin in the fourth quarter of last year will recover to 20.2% and 5% year-on-year.
China Merchants Securities International released a research report stating that they are optimistic about the rapid development of Hongteng Precision's (06088) AI server business by 2026. They believe that the company will fully benefit from the architectural upgrades of the GB300/VR200 servers this year, and they are positive about the company's strong product line in the fields of interconnection, power supply, liquid cooling, and CPO. The target price has been raised from HK$6.77 to HK$7.33, with a reiterated "buy" rating, citing the strong business prospects for the company this year, with AI interconnection, power supply, and cooling upgrades as key drivers of growth.
The research firm expects that AI-related business revenue at Hongteng Precision will grow at a compound rate of 95% between 2025 and 2027, accounting for 18% of the revenue by 2027 (compared to 6% in 2025). They forecast that in the fourth quarter of 2025, revenue and net profit will grow by 6% and 21% respectively, compared to 13% and 9% growth in the third quarter. Due to the improvement in the AI revenue structure, the research firm expects that Hongteng Precision's gross profit margin and net profit margin in the fourth quarter of last year will return to 20.2% and 5% respectively, compared to the previous year.
Related Articles

HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.
HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


